Global Targeted Drugs for Multiple Myeloma Market Growth (Status and Outlook) 2025-2031
According to this study, the global Targeted Drugs for Multiple Myeloma market size will reach US$ million by 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Targeted Drugs for Multiple Myeloma Industry Forecast” looks at past sales and reviews total world Targeted Drugs for Multiple Myeloma sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Multiple Myeloma sales for 2025 through 2031. With Targeted Drugs for Multiple Myeloma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drugs for Multiple Myeloma industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Multiple Myeloma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drugs for Multiple Myeloma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drugs for Multiple Myeloma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Multiple Myeloma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Multiple Myeloma.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Multiple Myeloma market by product type, application, key players and key regions and countries.
Segmentation by Type:
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Targeted Drugs for Multiple Myeloma Industry Forecast” looks at past sales and reviews total world Targeted Drugs for Multiple Myeloma sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Multiple Myeloma sales for 2025 through 2031. With Targeted Drugs for Multiple Myeloma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drugs for Multiple Myeloma industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Multiple Myeloma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drugs for Multiple Myeloma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drugs for Multiple Myeloma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Multiple Myeloma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Multiple Myeloma.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Multiple Myeloma market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Immunomodulator
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors (HDACI)
- Monoclonal Antibody
- Others
- Hospital
- Drug Center
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Celgene
- Exova
- Natco Pharma
- Intas Pharmaceuticals
- Indiabulls Pharmaceutical
- Cipla
- Glenmark Pharmaceuticals
- Dr Reddy's Laboratories
- Qilu Pharmaceutical
- Chia Tai-Tianqing
- Hanson Pharm
- Meidakang Huakang Pharmaceutical
- Shandong Kongfu Pharmaceutical
- J&J
- Takeda
- Amgen
- Bristol Myers Squibb
- Abbvie
- Seattle Genetics
- Karyopharm Therapeutics
- PDL BioPharma
- Roche
- Sumitomo
- Merck
- Biogen
- Schering-Plough
- Glaxo
- Chiron
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drugs for Multiple Myeloma Market Size (2020-2031)
2.1.2 Targeted Drugs for Multiple Myeloma Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Targeted Drugs for Multiple Myeloma by Country/Region (2020, 2024 & 2031)
2.2 Targeted Drugs for Multiple Myeloma Segment by Type
2.2.1 Immunomodulator
2.2.2 Proteasome Inhibitors
2.2.3 Histone Deacetylase Inhibitors (HDACI)
2.2.4 Monoclonal Antibody
2.2.5 Others
2.3 Targeted Drugs for Multiple Myeloma Market Size by Type
2.3.1 Targeted Drugs for Multiple Myeloma Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
2.4 Targeted Drugs for Multiple Myeloma Segment by Application
2.4.1 Hospital
2.4.2 Drug Center
2.4.3 Clinic
2.4.4 Others
2.5 Targeted Drugs for Multiple Myeloma Market Size by Application
2.5.1 Targeted Drugs for Multiple Myeloma Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
3 TARGETED DRUGS FOR MULTIPLE MYELOMA MARKET SIZE BY PLAYER
3.1 Targeted Drugs for Multiple Myeloma Market Size Market Share by Player
3.1.1 Global Targeted Drugs for Multiple Myeloma Revenue by Player (2020-2025)
3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player (2020-2025)
3.2 Global Targeted Drugs for Multiple Myeloma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUGS FOR MULTIPLE MYELOMA BY REGION
4.1 Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025)
4.2 Global Targeted Drugs for Multiple Myeloma Annual Revenue by Country/Region (2020-2025)
4.3 Americas Targeted Drugs for Multiple Myeloma Market Size Growth (2020-2025)
4.4 APAC Targeted Drugs for Multiple Myeloma Market Size Growth (2020-2025)
4.5 Europe Targeted Drugs for Multiple Myeloma Market Size Growth (2020-2025)
4.6 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025)
5.2 Americas Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025)
5.3 Americas Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025)
6.2 APAC Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025)
6.3 APAC Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025)
7.2 Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025)
7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drugs for Multiple Myeloma by Region (2020-2025)
8.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025)
8.3 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUGS FOR MULTIPLE MYELOMA MARKET FORECAST
10.1 Global Targeted Drugs for Multiple Myeloma Forecast by Region (2026-2031)
10.1.1 Global Targeted Drugs for Multiple Myeloma Forecast by Region (2026-2031)
10.1.2 Americas Targeted Drugs for Multiple Myeloma Forecast
10.1.3 APAC Targeted Drugs for Multiple Myeloma Forecast
10.1.4 Europe Targeted Drugs for Multiple Myeloma Forecast
10.1.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Forecast
10.2 Americas Targeted Drugs for Multiple Myeloma Forecast by Country (2026-2031)
10.2.1 United States Market Targeted Drugs for Multiple Myeloma Forecast
10.2.2 Canada Market Targeted Drugs for Multiple Myeloma Forecast
10.2.3 Mexico Market Targeted Drugs for Multiple Myeloma Forecast
10.2.4 Brazil Market Targeted Drugs for Multiple Myeloma Forecast
10.3 APAC Targeted Drugs for Multiple Myeloma Forecast by Region (2026-2031)
10.3.1 China Targeted Drugs for Multiple Myeloma Market Forecast
10.3.2 Japan Market Targeted Drugs for Multiple Myeloma Forecast
10.3.3 Korea Market Targeted Drugs for Multiple Myeloma Forecast
10.3.4 Southeast Asia Market Targeted Drugs for Multiple Myeloma Forecast
10.3.5 India Market Targeted Drugs for Multiple Myeloma Forecast
10.3.6 Australia Market Targeted Drugs for Multiple Myeloma Forecast
10.4 Europe Targeted Drugs for Multiple Myeloma Forecast by Country (2026-2031)
10.4.1 Germany Market Targeted Drugs for Multiple Myeloma Forecast
10.4.2 France Market Targeted Drugs for Multiple Myeloma Forecast
10.4.3 UK Market Targeted Drugs for Multiple Myeloma Forecast
10.4.4 Italy Market Targeted Drugs for Multiple Myeloma Forecast
10.4.5 Russia Market Targeted Drugs for Multiple Myeloma Forecast
10.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Forecast by Region (2026-2031)
10.5.1 Egypt Market Targeted Drugs for Multiple Myeloma Forecast
10.5.2 South Africa Market Targeted Drugs for Multiple Myeloma Forecast
10.5.3 Israel Market Targeted Drugs for Multiple Myeloma Forecast
10.5.4 Turkey Market Targeted Drugs for Multiple Myeloma Forecast
10.6 Global Targeted Drugs for Multiple Myeloma Forecast by Type (2026-2031)
10.7 Global Targeted Drugs for Multiple Myeloma Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Targeted Drugs for Multiple Myeloma Forecast
11 KEY PLAYERS ANALYSIS
11.1 Celgene
11.1.1 Celgene Company Information
11.1.2 Celgene Targeted Drugs for Multiple Myeloma Product Offered
11.1.3 Celgene Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Celgene Main Business Overview
11.1.5 Celgene Latest Developments
11.2 Exova
11.2.1 Exova Company Information
11.2.2 Exova Targeted Drugs for Multiple Myeloma Product Offered
11.2.3 Exova Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Exova Main Business Overview
11.2.5 Exova Latest Developments
11.3 Natco Pharma
11.3.1 Natco Pharma Company Information
11.3.2 Natco Pharma Targeted Drugs for Multiple Myeloma Product Offered
11.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Natco Pharma Main Business Overview
11.3.5 Natco Pharma Latest Developments
11.4 Intas Pharmaceuticals
11.4.1 Intas Pharmaceuticals Company Information
11.4.2 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
11.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Intas Pharmaceuticals Main Business Overview
11.4.5 Intas Pharmaceuticals Latest Developments
11.5 Indiabulls Pharmaceutical
11.5.1 Indiabulls Pharmaceutical Company Information
11.5.2 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Indiabulls Pharmaceutical Main Business Overview
11.5.5 Indiabulls Pharmaceutical Latest Developments
11.6 Cipla
11.6.1 Cipla Company Information
11.6.2 Cipla Targeted Drugs for Multiple Myeloma Product Offered
11.6.3 Cipla Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Cipla Main Business Overview
11.6.5 Cipla Latest Developments
11.7 Glenmark Pharmaceuticals
11.7.1 Glenmark Pharmaceuticals Company Information
11.7.2 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
11.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Glenmark Pharmaceuticals Main Business Overview
11.7.5 Glenmark Pharmaceuticals Latest Developments
11.8 Dr Reddy's Laboratories
11.8.1 Dr Reddy's Laboratories Company Information
11.8.2 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product Offered
11.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Dr Reddy's Laboratories Main Business Overview
11.8.5 Dr Reddy's Laboratories Latest Developments
11.9 Qilu Pharmaceutical
11.9.1 Qilu Pharmaceutical Company Information
11.9.2 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Qilu Pharmaceutical Main Business Overview
11.9.5 Qilu Pharmaceutical Latest Developments
11.10 Chia Tai-Tianqing
11.10.1 Chia Tai-Tianqing Company Information
11.10.2 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product Offered
11.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Chia Tai-Tianqing Main Business Overview
11.10.5 Chia Tai-Tianqing Latest Developments
11.11 Hanson Pharm
11.11.1 Hanson Pharm Company Information
11.11.2 Hanson Pharm Targeted Drugs for Multiple Myeloma Product Offered
11.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Hanson Pharm Main Business Overview
11.11.5 Hanson Pharm Latest Developments
11.12 Meidakang Huakang Pharmaceutical
11.12.1 Meidakang Huakang Pharmaceutical Company Information
11.12.2 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Meidakang Huakang Pharmaceutical Main Business Overview
11.12.5 Meidakang Huakang Pharmaceutical Latest Developments
11.13 Shandong Kongfu Pharmaceutical
11.13.1 Shandong Kongfu Pharmaceutical Company Information
11.13.2 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Shandong Kongfu Pharmaceutical Main Business Overview
11.13.5 Shandong Kongfu Pharmaceutical Latest Developments
11.14 J&J
11.14.1 J&J Company Information
11.14.2 J&J Targeted Drugs for Multiple Myeloma Product Offered
11.14.3 J&J Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 J&J Main Business Overview
11.14.5 J&J Latest Developments
11.15 Takeda
11.15.1 Takeda Company Information
11.15.2 Takeda Targeted Drugs for Multiple Myeloma Product Offered
11.15.3 Takeda Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Takeda Main Business Overview
11.15.5 Takeda Latest Developments
11.16 Amgen
11.16.1 Amgen Company Information
11.16.2 Amgen Targeted Drugs for Multiple Myeloma Product Offered
11.16.3 Amgen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 Amgen Main Business Overview
11.16.5 Amgen Latest Developments
11.17 Bristol Myers Squibb
11.17.1 Bristol Myers Squibb Company Information
11.17.2 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product Offered
11.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 Bristol Myers Squibb Main Business Overview
11.17.5 Bristol Myers Squibb Latest Developments
11.18 Abbvie
11.18.1 Abbvie Company Information
11.18.2 Abbvie Targeted Drugs for Multiple Myeloma Product Offered
11.18.3 Abbvie Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 Abbvie Main Business Overview
11.18.5 Abbvie Latest Developments
11.19 Seattle Genetics
11.19.1 Seattle Genetics Company Information
11.19.2 Seattle Genetics Targeted Drugs for Multiple Myeloma Product Offered
11.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 Seattle Genetics Main Business Overview
11.19.5 Seattle Genetics Latest Developments
11.20 Karyopharm Therapeutics
11.20.1 Karyopharm Therapeutics Company Information
11.20.2 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product Offered
11.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 Karyopharm Therapeutics Main Business Overview
11.20.5 Karyopharm Therapeutics Latest Developments
11.21 PDL BioPharma
11.21.1 PDL BioPharma Company Information
11.21.2 PDL BioPharma Targeted Drugs for Multiple Myeloma Product Offered
11.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.21.4 PDL BioPharma Main Business Overview
11.21.5 PDL BioPharma Latest Developments
11.22 Roche
11.22.1 Roche Company Information
11.22.2 Roche Targeted Drugs for Multiple Myeloma Product Offered
11.22.3 Roche Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.22.4 Roche Main Business Overview
11.22.5 Roche Latest Developments
11.23 Sumitomo
11.23.1 Sumitomo Company Information
11.23.2 Sumitomo Targeted Drugs for Multiple Myeloma Product Offered
11.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.23.4 Sumitomo Main Business Overview
11.23.5 Sumitomo Latest Developments
11.24 Merck
11.24.1 Merck Company Information
11.24.2 Merck Targeted Drugs for Multiple Myeloma Product Offered
11.24.3 Merck Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.24.4 Merck Main Business Overview
11.24.5 Merck Latest Developments
11.25 Biogen
11.25.1 Biogen Company Information
11.25.2 Biogen Targeted Drugs for Multiple Myeloma Product Offered
11.25.3 Biogen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.25.4 Biogen Main Business Overview
11.25.5 Biogen Latest Developments
11.26 Schering-Plough
11.26.1 Schering-Plough Company Information
11.26.2 Schering-Plough Targeted Drugs for Multiple Myeloma Product Offered
11.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.26.4 Schering-Plough Main Business Overview
11.26.5 Schering-Plough Latest Developments
11.27 Glaxo
11.27.1 Glaxo Company Information
11.27.2 Glaxo Targeted Drugs for Multiple Myeloma Product Offered
11.27.3 Glaxo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.27.4 Glaxo Main Business Overview
11.27.5 Glaxo Latest Developments
11.28 Chiron
11.28.1 Chiron Company Information
11.28.2 Chiron Targeted Drugs for Multiple Myeloma Product Offered
11.28.3 Chiron Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.28.4 Chiron Main Business Overview
11.28.5 Chiron Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drugs for Multiple Myeloma Market Size (2020-2031)
2.1.2 Targeted Drugs for Multiple Myeloma Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Targeted Drugs for Multiple Myeloma by Country/Region (2020, 2024 & 2031)
2.2 Targeted Drugs for Multiple Myeloma Segment by Type
2.2.1 Immunomodulator
2.2.2 Proteasome Inhibitors
2.2.3 Histone Deacetylase Inhibitors (HDACI)
2.2.4 Monoclonal Antibody
2.2.5 Others
2.3 Targeted Drugs for Multiple Myeloma Market Size by Type
2.3.1 Targeted Drugs for Multiple Myeloma Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
2.4 Targeted Drugs for Multiple Myeloma Segment by Application
2.4.1 Hospital
2.4.2 Drug Center
2.4.3 Clinic
2.4.4 Others
2.5 Targeted Drugs for Multiple Myeloma Market Size by Application
2.5.1 Targeted Drugs for Multiple Myeloma Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
3 TARGETED DRUGS FOR MULTIPLE MYELOMA MARKET SIZE BY PLAYER
3.1 Targeted Drugs for Multiple Myeloma Market Size Market Share by Player
3.1.1 Global Targeted Drugs for Multiple Myeloma Revenue by Player (2020-2025)
3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player (2020-2025)
3.2 Global Targeted Drugs for Multiple Myeloma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUGS FOR MULTIPLE MYELOMA BY REGION
4.1 Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025)
4.2 Global Targeted Drugs for Multiple Myeloma Annual Revenue by Country/Region (2020-2025)
4.3 Americas Targeted Drugs for Multiple Myeloma Market Size Growth (2020-2025)
4.4 APAC Targeted Drugs for Multiple Myeloma Market Size Growth (2020-2025)
4.5 Europe Targeted Drugs for Multiple Myeloma Market Size Growth (2020-2025)
4.6 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025)
5.2 Americas Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025)
5.3 Americas Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025)
6.2 APAC Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025)
6.3 APAC Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025)
7.2 Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025)
7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drugs for Multiple Myeloma by Region (2020-2025)
8.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025)
8.3 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUGS FOR MULTIPLE MYELOMA MARKET FORECAST
10.1 Global Targeted Drugs for Multiple Myeloma Forecast by Region (2026-2031)
10.1.1 Global Targeted Drugs for Multiple Myeloma Forecast by Region (2026-2031)
10.1.2 Americas Targeted Drugs for Multiple Myeloma Forecast
10.1.3 APAC Targeted Drugs for Multiple Myeloma Forecast
10.1.4 Europe Targeted Drugs for Multiple Myeloma Forecast
10.1.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Forecast
10.2 Americas Targeted Drugs for Multiple Myeloma Forecast by Country (2026-2031)
10.2.1 United States Market Targeted Drugs for Multiple Myeloma Forecast
10.2.2 Canada Market Targeted Drugs for Multiple Myeloma Forecast
10.2.3 Mexico Market Targeted Drugs for Multiple Myeloma Forecast
10.2.4 Brazil Market Targeted Drugs for Multiple Myeloma Forecast
10.3 APAC Targeted Drugs for Multiple Myeloma Forecast by Region (2026-2031)
10.3.1 China Targeted Drugs for Multiple Myeloma Market Forecast
10.3.2 Japan Market Targeted Drugs for Multiple Myeloma Forecast
10.3.3 Korea Market Targeted Drugs for Multiple Myeloma Forecast
10.3.4 Southeast Asia Market Targeted Drugs for Multiple Myeloma Forecast
10.3.5 India Market Targeted Drugs for Multiple Myeloma Forecast
10.3.6 Australia Market Targeted Drugs for Multiple Myeloma Forecast
10.4 Europe Targeted Drugs for Multiple Myeloma Forecast by Country (2026-2031)
10.4.1 Germany Market Targeted Drugs for Multiple Myeloma Forecast
10.4.2 France Market Targeted Drugs for Multiple Myeloma Forecast
10.4.3 UK Market Targeted Drugs for Multiple Myeloma Forecast
10.4.4 Italy Market Targeted Drugs for Multiple Myeloma Forecast
10.4.5 Russia Market Targeted Drugs for Multiple Myeloma Forecast
10.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Forecast by Region (2026-2031)
10.5.1 Egypt Market Targeted Drugs for Multiple Myeloma Forecast
10.5.2 South Africa Market Targeted Drugs for Multiple Myeloma Forecast
10.5.3 Israel Market Targeted Drugs for Multiple Myeloma Forecast
10.5.4 Turkey Market Targeted Drugs for Multiple Myeloma Forecast
10.6 Global Targeted Drugs for Multiple Myeloma Forecast by Type (2026-2031)
10.7 Global Targeted Drugs for Multiple Myeloma Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Targeted Drugs for Multiple Myeloma Forecast
11 KEY PLAYERS ANALYSIS
11.1 Celgene
11.1.1 Celgene Company Information
11.1.2 Celgene Targeted Drugs for Multiple Myeloma Product Offered
11.1.3 Celgene Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Celgene Main Business Overview
11.1.5 Celgene Latest Developments
11.2 Exova
11.2.1 Exova Company Information
11.2.2 Exova Targeted Drugs for Multiple Myeloma Product Offered
11.2.3 Exova Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Exova Main Business Overview
11.2.5 Exova Latest Developments
11.3 Natco Pharma
11.3.1 Natco Pharma Company Information
11.3.2 Natco Pharma Targeted Drugs for Multiple Myeloma Product Offered
11.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Natco Pharma Main Business Overview
11.3.5 Natco Pharma Latest Developments
11.4 Intas Pharmaceuticals
11.4.1 Intas Pharmaceuticals Company Information
11.4.2 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
11.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Intas Pharmaceuticals Main Business Overview
11.4.5 Intas Pharmaceuticals Latest Developments
11.5 Indiabulls Pharmaceutical
11.5.1 Indiabulls Pharmaceutical Company Information
11.5.2 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Indiabulls Pharmaceutical Main Business Overview
11.5.5 Indiabulls Pharmaceutical Latest Developments
11.6 Cipla
11.6.1 Cipla Company Information
11.6.2 Cipla Targeted Drugs for Multiple Myeloma Product Offered
11.6.3 Cipla Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Cipla Main Business Overview
11.6.5 Cipla Latest Developments
11.7 Glenmark Pharmaceuticals
11.7.1 Glenmark Pharmaceuticals Company Information
11.7.2 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
11.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Glenmark Pharmaceuticals Main Business Overview
11.7.5 Glenmark Pharmaceuticals Latest Developments
11.8 Dr Reddy's Laboratories
11.8.1 Dr Reddy's Laboratories Company Information
11.8.2 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product Offered
11.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Dr Reddy's Laboratories Main Business Overview
11.8.5 Dr Reddy's Laboratories Latest Developments
11.9 Qilu Pharmaceutical
11.9.1 Qilu Pharmaceutical Company Information
11.9.2 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Qilu Pharmaceutical Main Business Overview
11.9.5 Qilu Pharmaceutical Latest Developments
11.10 Chia Tai-Tianqing
11.10.1 Chia Tai-Tianqing Company Information
11.10.2 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product Offered
11.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Chia Tai-Tianqing Main Business Overview
11.10.5 Chia Tai-Tianqing Latest Developments
11.11 Hanson Pharm
11.11.1 Hanson Pharm Company Information
11.11.2 Hanson Pharm Targeted Drugs for Multiple Myeloma Product Offered
11.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Hanson Pharm Main Business Overview
11.11.5 Hanson Pharm Latest Developments
11.12 Meidakang Huakang Pharmaceutical
11.12.1 Meidakang Huakang Pharmaceutical Company Information
11.12.2 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Meidakang Huakang Pharmaceutical Main Business Overview
11.12.5 Meidakang Huakang Pharmaceutical Latest Developments
11.13 Shandong Kongfu Pharmaceutical
11.13.1 Shandong Kongfu Pharmaceutical Company Information
11.13.2 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Shandong Kongfu Pharmaceutical Main Business Overview
11.13.5 Shandong Kongfu Pharmaceutical Latest Developments
11.14 J&J
11.14.1 J&J Company Information
11.14.2 J&J Targeted Drugs for Multiple Myeloma Product Offered
11.14.3 J&J Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 J&J Main Business Overview
11.14.5 J&J Latest Developments
11.15 Takeda
11.15.1 Takeda Company Information
11.15.2 Takeda Targeted Drugs for Multiple Myeloma Product Offered
11.15.3 Takeda Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Takeda Main Business Overview
11.15.5 Takeda Latest Developments
11.16 Amgen
11.16.1 Amgen Company Information
11.16.2 Amgen Targeted Drugs for Multiple Myeloma Product Offered
11.16.3 Amgen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 Amgen Main Business Overview
11.16.5 Amgen Latest Developments
11.17 Bristol Myers Squibb
11.17.1 Bristol Myers Squibb Company Information
11.17.2 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product Offered
11.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 Bristol Myers Squibb Main Business Overview
11.17.5 Bristol Myers Squibb Latest Developments
11.18 Abbvie
11.18.1 Abbvie Company Information
11.18.2 Abbvie Targeted Drugs for Multiple Myeloma Product Offered
11.18.3 Abbvie Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 Abbvie Main Business Overview
11.18.5 Abbvie Latest Developments
11.19 Seattle Genetics
11.19.1 Seattle Genetics Company Information
11.19.2 Seattle Genetics Targeted Drugs for Multiple Myeloma Product Offered
11.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 Seattle Genetics Main Business Overview
11.19.5 Seattle Genetics Latest Developments
11.20 Karyopharm Therapeutics
11.20.1 Karyopharm Therapeutics Company Information
11.20.2 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product Offered
11.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 Karyopharm Therapeutics Main Business Overview
11.20.5 Karyopharm Therapeutics Latest Developments
11.21 PDL BioPharma
11.21.1 PDL BioPharma Company Information
11.21.2 PDL BioPharma Targeted Drugs for Multiple Myeloma Product Offered
11.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.21.4 PDL BioPharma Main Business Overview
11.21.5 PDL BioPharma Latest Developments
11.22 Roche
11.22.1 Roche Company Information
11.22.2 Roche Targeted Drugs for Multiple Myeloma Product Offered
11.22.3 Roche Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.22.4 Roche Main Business Overview
11.22.5 Roche Latest Developments
11.23 Sumitomo
11.23.1 Sumitomo Company Information
11.23.2 Sumitomo Targeted Drugs for Multiple Myeloma Product Offered
11.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.23.4 Sumitomo Main Business Overview
11.23.5 Sumitomo Latest Developments
11.24 Merck
11.24.1 Merck Company Information
11.24.2 Merck Targeted Drugs for Multiple Myeloma Product Offered
11.24.3 Merck Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.24.4 Merck Main Business Overview
11.24.5 Merck Latest Developments
11.25 Biogen
11.25.1 Biogen Company Information
11.25.2 Biogen Targeted Drugs for Multiple Myeloma Product Offered
11.25.3 Biogen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.25.4 Biogen Main Business Overview
11.25.5 Biogen Latest Developments
11.26 Schering-Plough
11.26.1 Schering-Plough Company Information
11.26.2 Schering-Plough Targeted Drugs for Multiple Myeloma Product Offered
11.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.26.4 Schering-Plough Main Business Overview
11.26.5 Schering-Plough Latest Developments
11.27 Glaxo
11.27.1 Glaxo Company Information
11.27.2 Glaxo Targeted Drugs for Multiple Myeloma Product Offered
11.27.3 Glaxo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.27.4 Glaxo Main Business Overview
11.27.5 Glaxo Latest Developments
11.28 Chiron
11.28.1 Chiron Company Information
11.28.2 Chiron Targeted Drugs for Multiple Myeloma Product Offered
11.28.3 Chiron Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2020-2025)
11.28.4 Chiron Main Business Overview
11.28.5 Chiron Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted Drugs for Multiple Myeloma Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Targeted Drugs for Multiple Myeloma Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Immunomodulator
Table 4. Major Players of Proteasome Inhibitors
Table 5. Major Players of Histone Deacetylase Inhibitors (HDACI)
Table 6. Major Players of Monoclonal Antibody
Table 7. Major Players of Others
Table 8. Targeted Drugs for Multiple Myeloma Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 10. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Table 11. Targeted Drugs for Multiple Myeloma Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 12. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 13. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Table 14. Global Targeted Drugs for Multiple Myeloma Revenue by Player (2020-2025) & ($ millions)
Table 15. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player (2020-2025)
Table 16. Targeted Drugs for Multiple Myeloma Key Players Head office and Products Offered
Table 17. Targeted Drugs for Multiple Myeloma Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025) & ($ millions)
Table 21. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Table 22. Global Targeted Drugs for Multiple Myeloma Revenue by Country/Region (2020-2025) & ($ millions)
Table 23. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Country/Region (2020-2025)
Table 24. Americas Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025) & ($ millions)
Table 25. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Country (2020-2025)
Table 26. Americas Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 27. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Table 28. Americas Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 29. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Table 30. APAC Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025) & ($ millions)
Table 31. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Table 32. APAC Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 33. APAC Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 34. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025) & ($ millions)
Table 35. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Country (2020-2025)
Table 36. Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 37. Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 38. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025) & ($ millions)
Table 39. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 40. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 41. Key Market Drivers & Growth Opportunities of Targeted Drugs for Multiple Myeloma
Table 42. Key Market Challenges & Risks of Targeted Drugs for Multiple Myeloma
Table 43. Key Industry Trends of Targeted Drugs for Multiple Myeloma
Table 44. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Region (2026-2031) & ($ millions)
Table 45. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Region (2026-2031)
Table 46. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Type (2026-2031) & ($ millions)
Table 47. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Application (2026-2031) & ($ millions)
Table 48. Celgene Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 49. Celgene Targeted Drugs for Multiple Myeloma Product Offered
Table 50. Celgene Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 51. Celgene Main Business
Table 52. Celgene Latest Developments
Table 53. Exova Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 54. Exova Targeted Drugs for Multiple Myeloma Product Offered
Table 55. Exova Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 56. Exova Main Business
Table 57. Exova Latest Developments
Table 58. Natco Pharma Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 59. Natco Pharma Targeted Drugs for Multiple Myeloma Product Offered
Table 60. Natco Pharma Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 61. Natco Pharma Main Business
Table 62. Natco Pharma Latest Developments
Table 63. Intas Pharmaceuticals Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 64. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
Table 65. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 66. Intas Pharmaceuticals Main Business
Table 67. Intas Pharmaceuticals Latest Developments
Table 68. Indiabulls Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 69. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 70. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 71. Indiabulls Pharmaceutical Main Business
Table 72. Indiabulls Pharmaceutical Latest Developments
Table 73. Cipla Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 74. Cipla Targeted Drugs for Multiple Myeloma Product Offered
Table 75. Cipla Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 76. Cipla Main Business
Table 77. Cipla Latest Developments
Table 78. Glenmark Pharmaceuticals Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 79. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
Table 80. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 81. Glenmark Pharmaceuticals Main Business
Table 82. Glenmark Pharmaceuticals Latest Developments
Table 83. Dr Reddy's Laboratories Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 84. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product Offered
Table 85. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 86. Dr Reddy's Laboratories Main Business
Table 87. Dr Reddy's Laboratories Latest Developments
Table 88. Qilu Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 89. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 90. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 91. Qilu Pharmaceutical Main Business
Table 92. Qilu Pharmaceutical Latest Developments
Table 93. Chia Tai-Tianqing Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 94. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product Offered
Table 95. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 96. Chia Tai-Tianqing Main Business
Table 97. Chia Tai-Tianqing Latest Developments
Table 98. Hanson Pharm Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 99. Hanson Pharm Targeted Drugs for Multiple Myeloma Product Offered
Table 100. Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 101. Hanson Pharm Main Business
Table 102. Hanson Pharm Latest Developments
Table 103. Meidakang Huakang Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 104. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 105. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 106. Meidakang Huakang Pharmaceutical Main Business
Table 107. Meidakang Huakang Pharmaceutical Latest Developments
Table 108. Shandong Kongfu Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 109. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 110. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 111. Shandong Kongfu Pharmaceutical Main Business
Table 112. Shandong Kongfu Pharmaceutical Latest Developments
Table 113. J&J Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 114. J&J Targeted Drugs for Multiple Myeloma Product Offered
Table 115. J&J Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 116. J&J Main Business
Table 117. J&J Latest Developments
Table 118. Takeda Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 119. Takeda Targeted Drugs for Multiple Myeloma Product Offered
Table 120. Takeda Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 121. Takeda Main Business
Table 122. Takeda Latest Developments
Table 123. Amgen Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 124. Amgen Targeted Drugs for Multiple Myeloma Product Offered
Table 125. Amgen Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 126. Amgen Main Business
Table 127. Amgen Latest Developments
Table 128. Bristol Myers Squibb Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 129. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product Offered
Table 130. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 131. Bristol Myers Squibb Main Business
Table 132. Bristol Myers Squibb Latest Developments
Table 133. Abbvie Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 134. Abbvie Targeted Drugs for Multiple Myeloma Product Offered
Table 135. Abbvie Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 136. Abbvie Main Business
Table 137. Abbvie Latest Developments
Table 138. Seattle Genetics Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 139. Seattle Genetics Targeted Drugs for Multiple Myeloma Product Offered
Table 140. Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 141. Seattle Genetics Main Business
Table 142. Seattle Genetics Latest Developments
Table 143. Karyopharm Therapeutics Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 144. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product Offered
Table 145. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 146. Karyopharm Therapeutics Main Business
Table 147. Karyopharm Therapeutics Latest Developments
Table 148. PDL BioPharma Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 149. PDL BioPharma Targeted Drugs for Multiple Myeloma Product Offered
Table 150. PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 151. PDL BioPharma Main Business
Table 152. PDL BioPharma Latest Developments
Table 153. Roche Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 154. Roche Targeted Drugs for Multiple Myeloma Product Offered
Table 155. Roche Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 156. Roche Main Business
Table 157. Roche Latest Developments
Table 158. Sumitomo Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 159. Sumitomo Targeted Drugs for Multiple Myeloma Product Offered
Table 160. Sumitomo Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 161. Sumitomo Main Business
Table 162. Sumitomo Latest Developments
Table 163. Merck Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 164. Merck Targeted Drugs for Multiple Myeloma Product Offered
Table 165. Merck Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 166. Merck Main Business
Table 167. Merck Latest Developments
Table 168. Biogen Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 169. Biogen Targeted Drugs for Multiple Myeloma Product Offered
Table 170. Biogen Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 171. Biogen Main Business
Table 172. Biogen Latest Developments
Table 173. Schering-Plough Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 174. Schering-Plough Targeted Drugs for Multiple Myeloma Product Offered
Table 175. Schering-Plough Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 176. Schering-Plough Main Business
Table 177. Schering-Plough Latest Developments
Table 178. Glaxo Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 179. Glaxo Targeted Drugs for Multiple Myeloma Product Offered
Table 180. Glaxo Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 181. Glaxo Main Business
Table 182. Glaxo Latest Developments
Table 183. Chiron Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 184. Chiron Targeted Drugs for Multiple Myeloma Product Offered
Table 185. Chiron Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 186. Chiron Main Business
Table 187. Chiron Latest Developments
Table 1. Targeted Drugs for Multiple Myeloma Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Targeted Drugs for Multiple Myeloma Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Immunomodulator
Table 4. Major Players of Proteasome Inhibitors
Table 5. Major Players of Histone Deacetylase Inhibitors (HDACI)
Table 6. Major Players of Monoclonal Antibody
Table 7. Major Players of Others
Table 8. Targeted Drugs for Multiple Myeloma Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 10. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Table 11. Targeted Drugs for Multiple Myeloma Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 12. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 13. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Table 14. Global Targeted Drugs for Multiple Myeloma Revenue by Player (2020-2025) & ($ millions)
Table 15. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player (2020-2025)
Table 16. Targeted Drugs for Multiple Myeloma Key Players Head office and Products Offered
Table 17. Targeted Drugs for Multiple Myeloma Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025) & ($ millions)
Table 21. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Table 22. Global Targeted Drugs for Multiple Myeloma Revenue by Country/Region (2020-2025) & ($ millions)
Table 23. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Country/Region (2020-2025)
Table 24. Americas Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025) & ($ millions)
Table 25. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Country (2020-2025)
Table 26. Americas Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 27. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Table 28. Americas Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 29. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Table 30. APAC Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025) & ($ millions)
Table 31. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Table 32. APAC Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 33. APAC Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 34. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025) & ($ millions)
Table 35. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Country (2020-2025)
Table 36. Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 37. Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 38. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025) & ($ millions)
Table 39. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025) & ($ millions)
Table 40. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025) & ($ millions)
Table 41. Key Market Drivers & Growth Opportunities of Targeted Drugs for Multiple Myeloma
Table 42. Key Market Challenges & Risks of Targeted Drugs for Multiple Myeloma
Table 43. Key Industry Trends of Targeted Drugs for Multiple Myeloma
Table 44. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Region (2026-2031) & ($ millions)
Table 45. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Region (2026-2031)
Table 46. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Type (2026-2031) & ($ millions)
Table 47. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Application (2026-2031) & ($ millions)
Table 48. Celgene Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 49. Celgene Targeted Drugs for Multiple Myeloma Product Offered
Table 50. Celgene Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 51. Celgene Main Business
Table 52. Celgene Latest Developments
Table 53. Exova Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 54. Exova Targeted Drugs for Multiple Myeloma Product Offered
Table 55. Exova Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 56. Exova Main Business
Table 57. Exova Latest Developments
Table 58. Natco Pharma Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 59. Natco Pharma Targeted Drugs for Multiple Myeloma Product Offered
Table 60. Natco Pharma Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 61. Natco Pharma Main Business
Table 62. Natco Pharma Latest Developments
Table 63. Intas Pharmaceuticals Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 64. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
Table 65. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 66. Intas Pharmaceuticals Main Business
Table 67. Intas Pharmaceuticals Latest Developments
Table 68. Indiabulls Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 69. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 70. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 71. Indiabulls Pharmaceutical Main Business
Table 72. Indiabulls Pharmaceutical Latest Developments
Table 73. Cipla Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 74. Cipla Targeted Drugs for Multiple Myeloma Product Offered
Table 75. Cipla Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 76. Cipla Main Business
Table 77. Cipla Latest Developments
Table 78. Glenmark Pharmaceuticals Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 79. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
Table 80. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 81. Glenmark Pharmaceuticals Main Business
Table 82. Glenmark Pharmaceuticals Latest Developments
Table 83. Dr Reddy's Laboratories Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 84. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product Offered
Table 85. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 86. Dr Reddy's Laboratories Main Business
Table 87. Dr Reddy's Laboratories Latest Developments
Table 88. Qilu Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 89. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 90. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 91. Qilu Pharmaceutical Main Business
Table 92. Qilu Pharmaceutical Latest Developments
Table 93. Chia Tai-Tianqing Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 94. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product Offered
Table 95. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 96. Chia Tai-Tianqing Main Business
Table 97. Chia Tai-Tianqing Latest Developments
Table 98. Hanson Pharm Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 99. Hanson Pharm Targeted Drugs for Multiple Myeloma Product Offered
Table 100. Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 101. Hanson Pharm Main Business
Table 102. Hanson Pharm Latest Developments
Table 103. Meidakang Huakang Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 104. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 105. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 106. Meidakang Huakang Pharmaceutical Main Business
Table 107. Meidakang Huakang Pharmaceutical Latest Developments
Table 108. Shandong Kongfu Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 109. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 110. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 111. Shandong Kongfu Pharmaceutical Main Business
Table 112. Shandong Kongfu Pharmaceutical Latest Developments
Table 113. J&J Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 114. J&J Targeted Drugs for Multiple Myeloma Product Offered
Table 115. J&J Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 116. J&J Main Business
Table 117. J&J Latest Developments
Table 118. Takeda Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 119. Takeda Targeted Drugs for Multiple Myeloma Product Offered
Table 120. Takeda Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 121. Takeda Main Business
Table 122. Takeda Latest Developments
Table 123. Amgen Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 124. Amgen Targeted Drugs for Multiple Myeloma Product Offered
Table 125. Amgen Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 126. Amgen Main Business
Table 127. Amgen Latest Developments
Table 128. Bristol Myers Squibb Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 129. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product Offered
Table 130. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 131. Bristol Myers Squibb Main Business
Table 132. Bristol Myers Squibb Latest Developments
Table 133. Abbvie Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 134. Abbvie Targeted Drugs for Multiple Myeloma Product Offered
Table 135. Abbvie Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 136. Abbvie Main Business
Table 137. Abbvie Latest Developments
Table 138. Seattle Genetics Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 139. Seattle Genetics Targeted Drugs for Multiple Myeloma Product Offered
Table 140. Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 141. Seattle Genetics Main Business
Table 142. Seattle Genetics Latest Developments
Table 143. Karyopharm Therapeutics Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 144. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product Offered
Table 145. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 146. Karyopharm Therapeutics Main Business
Table 147. Karyopharm Therapeutics Latest Developments
Table 148. PDL BioPharma Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 149. PDL BioPharma Targeted Drugs for Multiple Myeloma Product Offered
Table 150. PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 151. PDL BioPharma Main Business
Table 152. PDL BioPharma Latest Developments
Table 153. Roche Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 154. Roche Targeted Drugs for Multiple Myeloma Product Offered
Table 155. Roche Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 156. Roche Main Business
Table 157. Roche Latest Developments
Table 158. Sumitomo Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 159. Sumitomo Targeted Drugs for Multiple Myeloma Product Offered
Table 160. Sumitomo Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 161. Sumitomo Main Business
Table 162. Sumitomo Latest Developments
Table 163. Merck Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 164. Merck Targeted Drugs for Multiple Myeloma Product Offered
Table 165. Merck Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 166. Merck Main Business
Table 167. Merck Latest Developments
Table 168. Biogen Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 169. Biogen Targeted Drugs for Multiple Myeloma Product Offered
Table 170. Biogen Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 171. Biogen Main Business
Table 172. Biogen Latest Developments
Table 173. Schering-Plough Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 174. Schering-Plough Targeted Drugs for Multiple Myeloma Product Offered
Table 175. Schering-Plough Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 176. Schering-Plough Main Business
Table 177. Schering-Plough Latest Developments
Table 178. Glaxo Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 179. Glaxo Targeted Drugs for Multiple Myeloma Product Offered
Table 180. Glaxo Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 181. Glaxo Main Business
Table 182. Glaxo Latest Developments
Table 183. Chiron Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 184. Chiron Targeted Drugs for Multiple Myeloma Product Offered
Table 185. Chiron Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 186. Chiron Main Business
Table 187. Chiron Latest Developments
LIST OF FIGURES
Figure 1. Targeted Drugs for Multiple Myeloma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Targeted Drugs for Multiple Myeloma Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Targeted Drugs for Multiple Myeloma Sales Market Share by Country/Region (2024)
Figure 8. Targeted Drugs for Multiple Myeloma Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type in 2024
Figure 10. Targeted Drugs for Multiple Myeloma in Hospital
Figure 11. Global Targeted Drugs for Multiple Myeloma Market: Hospital (2020-2025) & ($ millions)
Figure 12. Targeted Drugs for Multiple Myeloma in Drug Center
Figure 13. Global Targeted Drugs for Multiple Myeloma Market: Drug Center (2020-2025) & ($ millions)
Figure 14. Targeted Drugs for Multiple Myeloma in Clinic
Figure 15. Global Targeted Drugs for Multiple Myeloma Market: Clinic (2020-2025) & ($ millions)
Figure 16. Targeted Drugs for Multiple Myeloma in Others
Figure 17. Global Targeted Drugs for Multiple Myeloma Market: Others (2020-2025) & ($ millions)
Figure 18. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application in 2024
Figure 19. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player in 2024
Figure 20. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Figure 21. Americas Targeted Drugs for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 22. APAC Targeted Drugs for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 23. Europe Targeted Drugs for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 24. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 25. Americas Targeted Drugs for Multiple Myeloma Value Market Share by Country in 2024
Figure 26. United States Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 27. Canada Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 28. Mexico Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 29. Brazil Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 30. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Region in 2024
Figure 31. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Figure 32. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Figure 33. China Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 34. Japan Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 35. South Korea Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 36. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 37. India Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 38. Australia Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 39. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Country in 2024
Figure 40. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Figure 41. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Figure 42. Germany Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 43. France Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 44. UK Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 45. Italy Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 46. Russia Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 47. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Figure 48. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Figure 49. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Figure 50. Egypt Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 51. South Africa Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 52. Israel Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 53. Turkey Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 54. GCC Countries Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 55. Americas Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 56. APAC Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 57. Europe Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 58. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 59. United States Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 60. Canada Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 61. Mexico Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 62. Brazil Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 63. China Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 64. Japan Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 65. Korea Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 66. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 67. India Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 68. Australia Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 69. Germany Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 70. France Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 71. UK Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 72. Italy Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 73. Russia Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 74. Egypt Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 75. South Africa Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 76. Israel Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 77. Turkey Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 78. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Type (2026-2031)
Figure 79. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Application (2026-2031)
Figure 80. GCC Countries Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 1. Targeted Drugs for Multiple Myeloma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Targeted Drugs for Multiple Myeloma Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Targeted Drugs for Multiple Myeloma Sales Market Share by Country/Region (2024)
Figure 8. Targeted Drugs for Multiple Myeloma Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type in 2024
Figure 10. Targeted Drugs for Multiple Myeloma in Hospital
Figure 11. Global Targeted Drugs for Multiple Myeloma Market: Hospital (2020-2025) & ($ millions)
Figure 12. Targeted Drugs for Multiple Myeloma in Drug Center
Figure 13. Global Targeted Drugs for Multiple Myeloma Market: Drug Center (2020-2025) & ($ millions)
Figure 14. Targeted Drugs for Multiple Myeloma in Clinic
Figure 15. Global Targeted Drugs for Multiple Myeloma Market: Clinic (2020-2025) & ($ millions)
Figure 16. Targeted Drugs for Multiple Myeloma in Others
Figure 17. Global Targeted Drugs for Multiple Myeloma Market: Others (2020-2025) & ($ millions)
Figure 18. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application in 2024
Figure 19. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player in 2024
Figure 20. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Figure 21. Americas Targeted Drugs for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 22. APAC Targeted Drugs for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 23. Europe Targeted Drugs for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 24. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size 2020-2025 ($ millions)
Figure 25. Americas Targeted Drugs for Multiple Myeloma Value Market Share by Country in 2024
Figure 26. United States Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 27. Canada Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 28. Mexico Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 29. Brazil Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 30. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Region in 2024
Figure 31. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Figure 32. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Figure 33. China Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 34. Japan Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 35. South Korea Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 36. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 37. India Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 38. Australia Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 39. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Country in 2024
Figure 40. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Figure 41. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Figure 42. Germany Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 43. France Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 44. UK Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 45. Italy Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 46. Russia Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 47. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2020-2025)
Figure 48. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2020-2025)
Figure 49. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2020-2025)
Figure 50. Egypt Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 51. South Africa Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 52. Israel Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 53. Turkey Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 54. GCC Countries Targeted Drugs for Multiple Myeloma Market Size Growth 2020-2025 ($ millions)
Figure 55. Americas Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 56. APAC Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 57. Europe Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 58. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 59. United States Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 60. Canada Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 61. Mexico Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 62. Brazil Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 63. China Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 64. Japan Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 65. Korea Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 66. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 67. India Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 68. Australia Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 69. Germany Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 70. France Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 71. UK Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 72. Italy Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 73. Russia Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 74. Egypt Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 75. South Africa Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 76. Israel Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 77. Turkey Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
Figure 78. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Type (2026-2031)
Figure 79. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Application (2026-2031)
Figure 80. GCC Countries Targeted Drugs for Multiple Myeloma Market Size 2026-2031 ($ millions)
More Publications
Global Transdermal and Transmucosal Drug Delivery Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
97 pages
